Database Evaluating Outcomes of Using Carbetocin as the Primary Uterotonic Following Cesarean Delivery
- Conditions
- CarbetocinUterotonicsUterine Atony With HemorrhageCesarean Section Complications
- Registration Number
- NCT03959436
- Lead Sponsor
- Maisonneuve-Rosemont Hospital
- Brief Summary
Carbetocin (Duratocin®) is a long-acting form of oxytocin, with a half-life almost 10 times longer. Studies have demonstrated that carbetocin diminishes the need for secondary uterotonic agents compared to oxytocin for cesarean delivery (CD). Despite certain Canadian guidelines recommending its use for elective CD, several Canadian centers and other countries have not adopted carbetocin. The purpose of this study is to prospectively gather electronic data on all CDs over a one year period, elective and emergent, in a single institution, and to evaluate the efficacy and other clinical outcomes when carbetocin is used as a first line uterotonic for all CDs. A database using Microsoft Dynamics CRM is available on smart phones and tablets. Data regarding additional uterotonic use and impact of carbetocin use during CD on intra and postoperative outcomes are gathered and analyzed. The primary outcome is the use of additional uterotonics in this population compared to that described in the literature for oxytocin as the primary uterotonic.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 612
- All Cesarean deliveries in the operating room.
- Vaginal deliveries and double set-up vaginal deliveries conducted in the operating room.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Use of additional uterotonics 24 hours The number of participants requiring additional uterotonics after using carbetocin as the initial uterotonic
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Maisonneuve-Rosemont hospital
🇨🇦Montreal, Quebec, Canada